Sino-US firm MicuRx Pharmaceuticals Inc. has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its in-house developed antibiotic, MRX-5, for the treatment of non-tuberculosis Mycobacterium (NTM) infections.
MRX-5: A Promising New Antibiotic for NTM
MRX-5 is a novel benzodiazole antibiotic specifically designed to combat infections caused by Mycobacterium, with a particular focus on the rising issue of NTM infections, which currently have limited treatment options. This new drug has demonstrated robust antibacterial activity in common NTM cases, offering a much-needed alternative for patients.
Positive Results in Animal and Human Studies
In both animal and human studies, MRX-5 has shown good safety and pharmacokinetics, making it a promising candidate for the treatment of NTM infections. The drug’s minimal interaction potential, virtually no resistance to drugs, and oral administration further enhance its appeal as an effective and convenient treatment option for patients.-Fineline Info & Tech
